IP Verse

An Sglt-2 Inhibitor For Use In The Treatment Of A Metabolic Disorder In Feline Animals - EP3862003

The patent EP3862003 was granted to Boehringer Ingelheim Vetmedica on Oct 25, 2023. The application was originally filed on Dec 15, 2014 under application number EP21155065A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3862003

BOEHRINGER INGELHEIM VETMEDICA
Application Number
EP21155065A
Filing Date
Dec 15, 2014
Status
Granted And Under Opposition
Sep 22, 2023
Grant Date
Oct 25, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ELANCOJul 24, 2024MURGITROYDADMISSIBLE

Patent Citations (51) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP1213296
DESCRIPTIONEP1344780
DESCRIPTIONEP1354888
DESCRIPTIONEP1489089
DESCRIPTIONWO0127128
DESCRIPTIONWO03099836
DESCRIPTIONWO2004007517
DESCRIPTIONWO2004080990
DESCRIPTIONWO2005012326
DESCRIPTIONWO2005092877
DESCRIPTIONWO2006034489
DESCRIPTIONWO2006064033
DESCRIPTIONWO2006117359
DESCRIPTIONWO2006117360
DESCRIPTIONWO2006120208
DESCRIPTIONWO2007025943
DESCRIPTIONWO2007028814
DESCRIPTIONWO2007031548
DESCRIPTIONWO2007093610
DESCRIPTIONWO2007114475
DESCRIPTIONWO2007128749
DESCRIPTIONWO2007140191
DESCRIPTIONWO2008002824
DESCRIPTIONWO2008013280
DESCRIPTIONWO2008042688
DESCRIPTIONWO2008049923
DESCRIPTIONWO2008055870
DESCRIPTIONWO2008055940
DESCRIPTIONWO2008069327
DESCRIPTIONWO2008116179
DESCRIPTIONWO2009014970
DESCRIPTIONWO2009022008
DESCRIPTIONWO2009022020
DESCRIPTIONWO2009035969
DESCRIPTIONWO2010023594
DESCRIPTIONWO2011039107
DESCRIPTIONWO2011039108
DESCRIPTIONWO2011117295
DESCRIPTIONWO2014016381
OPPOSITIONUS2011077212
OPPOSITIONWO2009076550
OPPOSITIONWO2010009243
OPPOSITIONWO2011153712
OPPOSITIONWO2012003811
OPPOSITIONWO2014161836
OPPOSITIONWO2015110402
SEARCHEP2368552
SEARCHWO2008116179
SEARCHWO2010048358
SEARCHWO2010092123
SEARCHWO2012062698

Non-Patent Literature (NPL) Citations (27) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- CURRY et al., Comp Biochem Physiol, (19820000), vol. 72A, no. 2, pages 333 - 338-
DESCRIPTION- HOENIG et al., Am J Physiol, (20110000), vol. 301, no. 6, pages R1798 - 1807-
DESCRIPTION- HOENIG, Mol Cell Endocrinol, (20020000), vol. 197, no. 1-2, pages 221 - 229-
DESCRIPTION- PALM CA et al., Vet Clin Small Anim, (20130000), vol. 43, pages 407 - 415-
DESCRIPTION- REUSCH CE et al., Schweizer Archiv fuer Tierheilkunde, (20110000), vol. 153811, pages 495 - 500-
DESCRIPTION- TANAKA et al., Vet Res Commun, (20050000), vol. 29, no. 6, pages 477 - 485-
DESCRIPTION- VERBRUGGHE et al., Crit Rev Food Sci Nutr, (20120000), vol. 52, no. 2, pages 172 - 182-
OPPOSITION- TASHIRO, Koji, "Null-Steering Technique in HAPS Systems for Spectrum Sharing with Terrestrial Mobile Networks", IEICE Technical Report, IEICE, JP, JP, (20210616), vol. 121, no. 72 (RCS2021-75), doi:10.1152/ajplegacy.1962.203.6.975, pages 267 - 272, XP009556586-
OPPOSITION- Verbrugghe Adronie, "Nutritional modulation of carbohydrate metabolism in domestic cats (Felis catus)", Doctoral Dissertation, Ghent University, (20090101), XP093197878-
OPPOSITION- Wilansky, "The effect of phenformin on ''prediabetes''", Metabolism, (1965), vol. 14, doi:10.1016/0026-0495(65)90006-5, page 7, XP026300580
OPPOSITION- Wilkinson Janine, Ajulo Damilola, Tamburrini Valeria, Gall Gwenaelle Le, Kimpe Kristof, Holm Rene, Belton Peter, Qi Sheng, "Lipid based intramuscular long-acting injectables: Current state of the art", European Journal of Pharmaceutical Sciences, Elsevier Amsterdam, NL, NL , (20221101), vol. 178, doi:10.1016/j.ejps.2022.106253, ISSN 0928-0987, page 106253, XP093095591
OPPOSITION- Schlienger Jean-Louis, Blicklé Jean-Frédéric, "De l’écorce des racines du pommier aux inhibiteurs du transporteur sodium-glucose de type 2 (SGLT2) : la folle histoire de la phloridzine = From apple tree roots bark to sodium-glucose transporter 2 (SGLT2) inhibitors: The crazy story of phloridzin", Médecine des Maladies Métaboliques, Elsevier Masson, (20240501), vol. 18, no. 3, doi:10.1016/j.mmm.2023.11.001, ISSN 2214-8477, pages 280 - 286, XP009556716
OPPOSITION- Kurosaki, "Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data", Pharmacology & Therapeutics , (20130404), vol. 139, doi:10.1016/j.pharmthera.2013.04.003, XP028564316
OPPOSITION- Anderson R. Aguillón, Alessandra Mascarello, Natanael D. Segretti, Hatylas F. Z De Azevedo, Cristiano R. W. Guimaraes, Leandro S. M. Miranda, Rodrigo O. M. A. De Souza, "Synthetic Strategies toward SGLT2 Inhibitors", Organic Process Research & Development, American Chemical Society, US, US , (20180420), vol. 22, no. 4, doi:10.1021/acs.oprd.8b00017, ISSN 1083-6160, pages 467 - 488, XP055648593
OPPOSITION- James F List, Jean M Whaley, "Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans", Kidney International, (20110301), vol. 79, doi:10.1038/ki.2010.512, ISSN 00852538, pages S20 - S27, XP055102046
OPPOSITION- Henson M. S., O'brien T. D., "Feline Models of Type 2 Diabetes Mellitus", ILAR JOURNAL, INSTITUTE FOR LABORATORY ANIMAL RESEARCH, US, US , (20060101), vol. 47, no. 3, doi:10.1093/ilar.47.3.234, ISSN 1084-2020, pages 234 - 242, XP093197870
OPPOSITION- Iskandar Idris, "Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug", Obesity and Metabolism, (2009), vol. 11, doi:10.1111/j.1463-1326.2008.00982.x, XP007915350
OPPOSITION- Obermeier, Yao, Khanna, Koplowitz, Zhu, Li, Komoroski, Kasichayanula, Discenza, Washburn, Meng, Ellsworth, Whaley, Humphreys, "In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans", Drug metabolism and disposition: the biological fate of chemicals, American Society for Pharmacology and Experimental Therapeutics, USA, USA , (20100317), vol. 38, no. 3, doi:10.1124/dmd.109.029165, ISSN 1521-009X, pages 405 - 414, XP009556567
OPPOSITION- Dohan F.C., F.D.W. Lukens, "Lesions of the Pancreatic Islets Produced in Cats by Administration of Glucose", Science, (19470214), vol. 105, no. 2720, doi:10.1126/science.105.2720.183, pages 183 - 183, XP093197861
OPPOSITION- ROSSETTI L., ET AL., "CORRECTION OF HYPERGLYCEMIA WITH PHLORIZIN NORMALIZES TISSUE SENSITIVITY TO INSULIN IN DIABETIC RATS.", The Journal of Clinical Investigation, B M J Group, (19870501), vol. 79., doi:10.1172/JCI112981, pages 1510 - 1515., XP000617166
OPPOSITION- Gallo Linda A, Wright Ernest M, Vallon Volker, "Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences", DIABETES AND VASCULAR DISEASE RESEARCH, MEDINEWS, BIRMINGHAM, GB, GB , (20150301), vol. 12, no. 2, doi:10.1177/1479164114561992, ISSN 1479-1641, pages 78 - 89, XP093197873
OPPOSITION- FDW Lukens, FC Dohan, MW Wolcott, "Pituitary-Diabetes in the cat: recovery following phlorhizin treatment ", Endocrinology, The Endocrine Society, US, US , (19430601), vol. 32, no. 6, doi:10.1210/endo-32-6-475, ISSN 0013-7227, pages 475 - 487, XP009556717
OPPOSITION- ASANO TOMOICHIRO ET AL, "SGLT as a therapeutic target", Drugs of the Future, Prous Science, ES, ES , (20040501), vol. 29, no. 5, doi:10.1358/dof.2004.029.05.850959, ISSN 0377-8282, pages 461 - 466, XP002502075
OPPOSITION- HANDLON A L, "Sodium glucose co-transporter 2 (SGLT2) inhibitors as potential antidiabetic agents", EXPERT OPINION ON THERAPEUTIC PATENTS, Taylor & Francis, GB, GB , (20050101), vol. 15, no. 11, doi:10.1517/13543776.15.11.1531, ISSN 1354-3776, pages 1531 - 1540, XP002388315
OPPOSITION- Lukens F.D.W., Stanley N. Cohen, Yoshio Goto, "Steroid Diabetes in the Cat - Protection of the Islets by Insulin or Phlorhizin", Diabetes, (19610501), vol. 19, doi:10.2337/diab.10.3.182, pages 182 - 189, XP093197867
OPPOSITION- Bjornvad Charlotte R., Dorte H Nielsen, P Jane Armstrong, Fintan Mcevoy, Kirsten M Hoelmkjaer, Kathrine S Jensen, Gitte F Pedersen, Annemarie T Kristensen, "Evaluation of a nine-point body condition scoring system in physically inactive pet cats", AJVR, (20110401), vol. 72, no. 4, doi:10.2460/ajvr.72.4.433, pages 433 - 437, XP093197875
SEARCH- M. OSTO ET AL, "Diabetes from humans to cats", GENERAL AND COMPARATIVE ENDOCRINOLOGY, (20130201), vol. 182, doi:10.1016/j.ygcen.2012.11.019, ISSN 0016-6480, pages 48 - 53, XP055102098 [Y] 1-15 * abstract; p. 52 l.30-35 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents